J&J Massachusetts Talc Verdict: Jury Awards $1.9 Million for Mesothelioma but Rejects Death Claim

The J&J Massachusetts talc verdict is a split decision: on Friday, November 6, 2026, a jury in Massachusetts Superior Court in Boston found that Johnson & Johnson's talc caused a former talcum powder user's mesothelioma but not her death, and ordered the company to pay about $1.9 million, Law360 reported. The family had asked for $60 million, J&J says it will appeal "immediately," and the finding on causation of death is what kept the award small, because it removes both wrongful death damages and any punitive award under Massachusetts law.

The case, reported as Haddad v. Johnson & Johnson, is the third Massachusetts mesothelioma trial since June 2025 to end in a plaintiff's verdict against J&J, after an $8 million award to Janice Paluzzi and a $42.6 million award to Paul and Kathryn Lovell. It is also the first talc mesothelioma verdict in the country since an Ohio jury cleared J&J on October 23, 2026, and it lands while the company's separate ovarian cancer deal, which does not cover mesothelioma, is still short of its 95% participation condition. This piece sets out what is known about the trial and what is not, explains why the jury could find the disease but not the death, compares the award with J&J's recent mesothelioma record, walks through Massachusetts damages and post-trial rules, and closes with what the result means for plaintiffs' firms, defendants and funders.

How much did the Massachusetts jury award against J&J in the talc case?

About $1.9 million. Law360 reported that a Massachusetts jury "said Friday that Johnson & Johnson owes $1.9 million for causing the mesothelioma, but not the death," of a former talcum powder user who also had a heart condition. HarrisMartin, which covers talc litigation, reported the award as $1.8 million and said the Suffolk County Superior Court jury returned it on November 6, one day after closing arguments.

The $100,000 gap between the two reports has not been resolved in public coverage. The likeliest explanations are rounding of a figure between $1.8 million and $1.9 million, or a difference between the jury's gross figure and a total after some line item, but neither outlet's full verdict breakdown has been published. Until the verdict slip or judgment is available, the safest statement is that the jury awarded roughly $1.8 million to $1.9 million in compensatory damages, with no reported punitive award.

Either figure is a small fraction of what the family requested. During closing arguments on Thursday, November 5, 2026, counsel told the jury that J&J should pay $60 million for the woman's death, Law360 reported. At $1.9 million, the verdict is about 3.2% of that ask; at $1.8 million, about 3%.

Who was the plaintiff in the Massachusetts J&J talc trial?

The trial that ended on November 6 is reported as Haddad v. Johnson & Johnson. Law.com reported that it opened on Monday, October 19, 2026 in Suffolk County Superior Court, with plaintiffs' counsel Aaron Chapman of Dean Omar Branham Shirley telling jurors that Johnson's Baby Powder caused Winifred Haddad, a nurse and mother of four sons, to develop mesothelioma at age 66. She died in 2020. Courtroom View Network, which webcast the trial, listed it as a cosmetic talc jury trial and carries a docket number of 2081CV02285.

Three separate reports line up on the same case: Law.com's opening-day story (a Suffolk County mesothelioma trial over a nurse's death), Law360's closing-argument and verdict stories (a woman with mesothelioma and heart problems, a death claim, a Massachusetts state jury), and HarrisMartin's verdict report (a former nurse, Suffolk County, November 6). None of the verdict-day reports published so far names the plaintiff in its headline or opening lines, so the identification rests on that convergence rather than on a published verdict form.

Several details have not been reported and are not stated here: the presiding judge, the precise verdict-slip questions, the split between categories of compensatory damages, whether any co-defendant or retailer stayed in the case through verdict, the jury's vote, and whether J&J's former consumer health unit, Kenvue, was a named party. J&J retained talc liabilities when it separated Kenvue and indemnifies it for talc costs in the United States and Canada, according to its securities filings, so the economic exposure sits with J&J either way.

Why did the jury find J&J caused mesothelioma but not the death?

The jury accepted the plaintiff's core product case, that asbestos in J&J's talc caused Haddad's mesothelioma, but did not accept that the mesothelioma caused her death. The defense theory pointed the jury toward an alternative cause of death. Law.com reported that J&J's trial counsel, Will Stute of King & Spalding, cast doubt on the plaintiffs' experts and on what caused Haddad's death, and Law360's coverage noted that she had a heart condition alongside her cancer.

That is an unusual combination. In most talc mesothelioma trials, the fight is over specific causation of the disease: whether the plaintiff's particular product contained asbestos and whether that exposure was a substantial contributing factor. Mesothelioma is a signature disease of asbestos exposure and is usually fatal, so once a jury finds the product caused the cancer, it typically follows that the cancer caused the death. Here, the jury separated the two questions. It found specific causation for the disease and rejected causation for the death, which suggests the jurors were persuaded that a cardiac event or other condition was the medical cause of death at the time Haddad died in 2020, even if she was living with mesothelioma.

The split matters far more than it might seem, because in Massachusetts the death finding is the gateway to most of the money in a fatal-asbestos case.

Why was the verdict so much lower than the $60 million requested?

The $60 million ask was framed around the death; the jury did not find the death. Massachusetts separates the recovery in a fatal-injury case into two strands. The wrongful death statute, G.L. c. 229, § 2, lets the estate's representative recover for the death itself on behalf of statutory beneficiaries, including the fair monetary value of the decedent to them, measured by lost services, protection, care, companionship, comfort, guidance, counsel and advice, plus funeral and burial costs and, where the facts support it, punitive damages. A separate provision, G.L. c. 229, § 6, preserves recovery in the same action for the decedent's own conscious pain and suffering before death.

When a jury finds the defendant caused the injury but not the death, the § 2 strand falls away. What remains are damages for the injury itself: the decedent's conscious suffering from the disease, and related losses tied to the illness rather than to the death. For four sons, the loss-of-companionship and loss-of-guidance damages that typically drive large wrongful death verdicts depend on the death finding. Without it, a plaintiff's damages model built around those losses collapses to the narrower survival component.

The reported award is consistent with that structure. A total near $1.9 million is the kind of figure that compensates a period of illness and suffering rather than a death, while the $60 million figure reflects what a wrongful death verdict with a punitive component could have looked like. Neither outlet has published the jury's line-item split, so this reading is analysis of the structure of the verdict, not a report of how the jury allocated the money.

Are punitive damages available in Massachusetts talc cases?

Only through statute, and in a death case that means only through the wrongful death statute. Massachusetts does not allow punitive damages under common law; they are recoverable only where the Legislature has expressly authorized them. The wrongful death statute is one of those authorizations: G.L. c. 229, § 2 permits punitive damages of not less than $5,000 where the death was caused by the defendant's malicious, willful, wanton or reckless conduct or by its gross negligence.

The Supreme Judicial Court's tobacco decision in Evans v. Lorillard Tobacco Co. (2013) underscores the link: a punitive award under § 2 requires that the gross negligence or reckless conduct be what caused the wrongful death. Product-liability claims in Massachusetts are usually pleaded as negligence and breach of the implied warranty of merchantability, Massachusetts' functional equivalent of strict liability, and neither theory carries its own punitive remedy outside § 2.

The practical consequence for the J&J Massachusetts talc verdict is direct. Once the jury found no causation of death, punitive damages were legally unavailable, whatever the jury thought of J&J's conduct. That stands in sharp contrast to the nine- and ten-figure punitive components that produced headline verdicts in Maryland, California and Oregon, and explains why Massachusetts talc awards, including the $42.6 million Lovell verdict, have been compensatory-driven.

Will Johnson & Johnson appeal the Massachusetts talc verdict?

Yes. HarrisMartin reported that Aviva Wein, J&J's worldwide vice president and head of litigation, said the company would "immediately" appeal. That matches J&J's stated approach to every adverse talc verdict: the company maintains its talc never contained asbestos and does not cause cancer, and its securities filings say it believes it has strong legal grounds to contest the talc verdicts it has appealed.

In Massachusetts, the path runs through post-trial motions first. Under the Massachusetts Rules of Civil Procedure, a motion for judgment notwithstanding the verdict under Rule 50(b) or for a new trial or remittitur under Rule 59 must be served within 10 days after entry of judgment, and a timely motion suspends the 30-day period to file a notice of appeal under Massachusetts Rule of Appellate Procedure 4(a). Appeals go to the Appeals Court, with the possibility of direct appellate review or further appellate review in the Supreme Judicial Court.

The family also has options. A plaintiff disappointed by a death-causation finding can move for a new trial on the ground that the finding was against the weight of the evidence, though the standard is demanding and trial judges rarely overturn a jury's resolution of competing medical testimony. Whatever the post-trial outcome, the J&J Massachusetts talc verdict will be tested on appeal. Expect any appeal from J&J to focus on the plaintiff's expert proof that the specific talc contained asbestos and caused the disease, which is the same ground J&J has pressed in the Paluzzi and Lovell appeals; no appellate ruling in either of those cases had been reported as of this writing.

How much could interest add to the Massachusetts talc judgment?

Potentially a great deal. Massachusetts adds statutory interest at 12% per year to damages for personal injury, under G.L. c. 231, § 6B, running from the date the action was commenced rather than from the verdict. The Supreme Judicial Court upheld that rate against constitutional challenge in Green v. Philip Morris USA in 2023. Because CVN's docket number indicates a 2020 filing, interest at 12% simple over roughly six years could add on the order of 70% to the compensatory award once judgment enters, which would put a $1.9 million verdict in the range of $3 million or more.

Two caveats apply. First, the filing date has not been reported, so the multiplier is an estimate. Second, how the interest statutes apply to a verdict in an action brought under the death statute but resolved on injury damages is a technical question; the death statute has its own interest provision, G.L. c. 229, § 11, and courts have historically addressed which rate governs in combined death-and-suffering actions. The point for practitioners is that the headline verdict is a floor, not a final number, and that each month of appellate delay adds to J&J's exposure at a rate well above market.

How does the J&J Massachusetts talc verdict compare with other mesothelioma verdicts?

It is small by the standards of recent mesothelioma trials against J&J, and it follows an Ohio defense verdict two weeks earlier. The table sets the Haddad result against reported verdicts and appellate rulings since 2024. Figures are as reported at the time of verdict; several have since been reduced or are on appeal.

Case / forum	Date	Outcome	Reported detail
Kyung Lee v. Bi-Mart Corp. (Multnomah County, Ore.)	June 3, 2024	Plaintiff verdict, $260 million	$60 million compensatory, $200 million punitive
Paluzzi (Suffolk County, Mass.)	June 2025	Plaintiff verdict, $8 million	Negligence and breach of warranty; J&J appealed
Lovell (Boston, Mass.)	July 29, 2025	Plaintiff verdict, about $42.6 million	All compensatory: pain and suffering, medical costs, loss of consortium; J&J appealed
Moore (Los Angeles County, Cal.)	October 2025	Plaintiff verdict, $966 million	$16 million compensatory, $950 million punitive; post-trial rulings pending or contested
Craft (Baltimore City, Md.)	December 2025	Plaintiff verdict, more than $1.5 billion	$59.84 million compensatory; $1 billion punitive against J&J
Houghton Carley (Ramsey County, Minn.)	December 2025	Plaintiff verdict, $65.5 million	New-trial motion later denied
Lozano (Los Angeles County, Cal.)	June 9, 2026	Plaintiff verdict, $32 million	100% of fault assigned to J&J
Garcia (Ill. App. Ct., 1st Dist.)	July 2026	$45 million verdict affirmed	$33 million survival, $12 million wrongful death
Roy (Orleans Parish, La.)	August 2026	Plaintiff verdict, $10 million	Fault shared; J&J share reported near $1.2 million
Ohio state court	October 23, 2026	Defense verdict	Wrongful death claim rejected
Haddad (Suffolk County, Mass.)	November 6, 2026	Plaintiff verdict, about $1.9 million	Disease caused by talc; death not; $60 million requested

Three patterns stand out. First, all three Massachusetts mesothelioma verdicts in the table went for the plaintiff on causation of the disease, a stronger plaintiff record than J&J has had in several other venues, even though the dollar figures vary widely. Second, the largest verdicts in the table were driven by punitive damages, which Massachusetts law confines to death cases; Massachusetts outcomes depend on compensatory damages alone. Third, the Garcia affirmance in Illinois shows how a survival award and a wrongful death award can sit side by side in a single judgment; the Haddad jury effectively returned only the first.

Massachusetts has not been uniformly favorable to plaintiffs: Legal Newsline has reported a separate Massachusetts trial in which a jury rejected causation for a woman's fatal cancer while finding that Johnson's Baby Powder should have carried a warning label. Together with Haddad, it shows Massachusetts juries parsing causation questions closely rather than treating liability and damages as a package.

Does the J&J talc settlement cover mesothelioma claims?

No. J&J's proposed resolution of the remaining talc litigation, announced July 27, 2026, is limited to ovarian cancer and gynecological claims; mesothelioma claims were carved out and continue to be tried individually in state courts. J&J's quarterly report for the period ended September 27, 2026 says the ovarian resolution does not affect the mesothelioma docket, which "remains ongoing," and reports roughly 76,500 plaintiffs with pending talc-related claims in the United States.

The ovarian deal is generally reported at $5.5 billion, the figure J&J took as a litigation charge in the third quarter; Law.com has described it as a $5.8 billion settlement. It is conditioned on at least 95% participation among remaining claimants. Lead plaintiffs' counsel told the multidistrict litigation's magistrate judge in October 2026 that 313 firms representing about 66,500 claimants, roughly 87.5%, had signed on. The MDL, In re Johnson & Johnson Talcum Powder Products (MDL No. 2738, D.N.J.), had about 69,340 pending actions as of October 1, 2026.

The separation matters for valuing the Haddad verdict. It is not a signal about ovarian claims, whose causation evidence and settlement matrix are different. It is a data point for the mesothelioma docket, where J&J has historically settled most cases and tried a steady stream, and where single-plaintiff verdicts, both large and small, set the market for future settlements.

Talc mesothelioma litigation in Massachusetts: the legal framework

Massachusetts has become a regular venue for talc mesothelioma trials, and several features of its law shape outcomes.

Liability theories. Massachusetts does not recognize strict products liability in tort as such; the implied warranty of merchantability under G.L. c. 106, § 2-314 performs that function and is interpreted to be congruent in nearly all respects with the strict-liability principles of the Restatement. Plaintiffs typically plead negligence (including failure to warn and design defect) together with breach of warranty, which is how the Paluzzi and Lovell juries framed their findings.

Causation. Massachusetts asbestos cases apply a substantial-factor test for specific causation. The plaintiff must show exposure to the defendant's product and that the exposure was a substantial contributing factor in causing the disease. The heart of most talc trials, including Haddad, is whether the particular baby powder the plaintiff used contained asbestos at all, which turns on the competing testing evidence that both sides have developed over a decade of litigation, and on expert admissibility rulings under the Lanigan standard, the state's counterpart to Daubert.

Damages. There is no general cap on compensatory damages for personal injury in Massachusetts outside narrow contexts such as the medical malpractice cap on non-economic damages, which does not apply to product cases. Juries therefore have wide latitude on conscious suffering and loss of consortium, as the reported $24 million in past and future pain-and-suffering components of the Lovell award showed. Punitive damages, as noted, are confined to death cases under § 2.

Interest. The 12% statutory interest rate, among the highest in the country, gives plaintiffs leverage during appeals and shifts the economics of post-verdict settlement.

What the J&J Massachusetts talc verdict means for plaintiffs' firms, defendants and funders

For plaintiffs' firms trying mesothelioma cases

The J&J Massachusetts talc verdict confirms that Massachusetts juries will find for plaintiffs on asbestos-in-talc causation, which is the hardest liability question in these trials. It also shows the cost of letting cause of death become a contested issue. Where a decedent had serious comorbidities, the death-causation question needs the same evidentiary attention as product identification: treating-physician testimony, death certificate analysis and pathology tying the terminal course to the cancer. A damages presentation that rests almost entirely on wrongful death and punitive damages leaves little to fall back on if the jury separates the disease from the death; firms may weigh building a fuller conscious-suffering record so that the survival claim can carry weight on its own.

For J&J and other talc defendants

The defense lost the core causation fight but won the damages fight. An alternative-cause-of-death strategy, where the medical record supports it, can neutralize the punitive exposure that drives the largest verdicts, even in a venue where juries have accepted asbestos-contamination evidence three times running. That will not transfer to every case; most mesothelioma decedents die of the disease. But for older plaintiffs with cardiac, pulmonary or other serious conditions, the Haddad result gives defendants a template, and it adds to a short string of better outcomes for J&J this fall following the Ohio defense verdict.

For litigation funders and settlement modeling

Funders and firms pricing mesothelioma portfolios now have a Massachusetts data point that is an order of magnitude below Lovell. A portfolio valuation that averages Massachusetts verdicts without adjusting for whether death causation is in dispute will misprice cases. The 12% interest rate partly offsets a low verdict over a long appeal, but it compounds on a much smaller base. Funders exposed to cases with comorbid decedents may want to review how their underwriting accounts for the risk that a jury separates disease from death, a risk the Haddad verdict has now made concrete.

For claimants deciding between the ovarian deal and trial

The Haddad verdict does not directly bear on ovarian claimants, because the cases involve different diseases, causation evidence and settlement terms. What it does illustrate is the variance of individual trials: within three weeks, J&J has faced a defense verdict in Ohio and a plaintiff's verdict in Massachusetts that came in at about 3% of the family's request. Variance of that kind is a large part of why aggregate deals with participation thresholds exist, and claimants' counsel weighing opt-outs will see it as part of the trial-risk picture.

What to watch next

• The verdict slip and judgment. The line-item split will show how the jury valued conscious suffering and whether any category was rejected, and will resolve the $1.8 million versus $1.9 million reporting gap.
• Post-trial motions. J&J's Rule 50(b) and Rule 59 motions, and any cross-motion by the family on the death-causation finding, will be due within 10 days after judgment enters.
• Interest calculation. The filing date and the court's treatment of the interest statutes will determine the size of the judgment J&J actually appeals.
• Paluzzi and Lovell appeals. An appellate ruling in either earlier Massachusetts case would be the first word from a Massachusetts appellate court on J&J's talc causation arguments and would frame the Haddad appeal.
• The ovarian deal. J&J's show-cause response in MDL 2738 is due November 19, 2026, and participation updates against the 95% threshold continue; neither changes the mesothelioma docket, but both affect J&J's overall talc reserve and its appetite for trial.

FAQ

How much did the Massachusetts jury award against J&J in the talc mesothelioma case?

About $1.9 million, according to Law360; HarrisMartin reported $1.8 million. The jury returned the verdict on November 6, 2026 in Massachusetts Superior Court in Boston, finding J&J's talc caused the woman's mesothelioma but not her death.

Why did the jury find J&J caused mesothelioma but not the death?

The jury accepted that asbestos in J&J's talc caused the cancer but was not persuaded that the cancer caused her 2020 death. Reports noted she also had a heart condition, and J&J's counsel challenged what caused her death.

Why was the Massachusetts talc verdict so much lower than the $60 million requested?

The $60 million request was built around the death. Without a finding that J&J caused the death, wrongful death damages under G.L. c. 229, § 2 and the punitive damages that statute allows were unavailable, leaving injury damages only.

Will Johnson & Johnson appeal the Massachusetts talc verdict?

Yes. J&J's head of litigation, Aviva Wein, said the company would "immediately" appeal. Post-trial motions in Massachusetts are due within 10 days after judgment enters, and a notice of appeal within 30 days after those motions are decided.

Does the J&J talc settlement cover mesothelioma claims?

No. J&J's proposed ovarian cancer settlement, generally reported at $5.5 billion and conditioned on 95% participation, excludes mesothelioma, and J&J's latest quarterly filing says the mesothelioma docket "remains ongoing."

Are punitive damages available in Massachusetts talc cases?

Only in death cases. Massachusetts allows punitive damages only where a statute authorizes them, and the wrongful death statute permits them only when gross negligence or reckless conduct caused the death, which the Haddad jury did not find.